Virbac, today announced the successful completion of its divestment of the U.S. rights to its parasiticides for dogs: SENTINEL^® FLAVOR TABS^® and SENTINEL^® SPECTRUM^® to MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK). The consideration received for the transaction amounted to approximately US $400 million, subject to customary closing adjustments, settled in cash.

Thanks to the ongoing support of The Every Dog Project, Virbac is expanding the initiative to become The Every Pet Project. It will now include all pets, with the intention of making an even bigger impact.

Francois Fournier, CEO of Virbac North America, explained the thinking behind the expansion: 
“The Every Pet Project will help us do more for the communities we serve and enable us to improve the quality of care for pets that need it the most.”

Through The Every Pet Project, Virbac’s goal is to help ensure that EVERY PET, EVERYWHERE enjoys a happy  life and is able to receive the care and protection they deserve. By engaging with clinics, pet owners, and various organizations, Virbac is striving to raise awareness about the project, help as many charities as possible, and draw attention to the unmet medical needs facing pets today.